The University of Queensland, Delivery of Drugs and Genes Group, Australian Institute for Bioengineering and Nanotechnology, Brisbane, Queensland 4072, Australia.
J Control Release. 2010 Dec 20;148(3):327-33. doi: 10.1016/j.jconrel.2010.09.001. Epub 2010 Sep 17.
HSV-2-gD2 DNA vaccine was precisely delivered to immunologically sensitive regions of the skin epithelia using dry-coated microprojection arrays. These arrays delivered a vaccine payload to the epidermis and the upper dermis of mouse skin. Immunomicroscopy results showed that, in 43 ± 5% of microprojection delivery sites, the DNA vaccine was delivered to contact with professional antigen presenting cells in the epidermal layer. Associated with this efficient delivery of the vaccine into the vicinity of the professional antigen presenting cells, we achieved superior antibody responses and statistically equal protection rate against an HSV-2 virus challenge, when compared with the mice immunized with intramuscular injection using needle and syringe, but with less than 1/10th of the delivered antigen.
使用干式涂布微针阵列，将 HSV-2-gD2 DNA 疫苗精确递送至皮肤上皮的免疫敏感区域。这些阵列将疫苗有效载荷递送至小鼠皮肤的表皮和上部真皮。免疫显微镜检查结果显示，在 43±5%的微针递药部位，DNA 疫苗被递送至表皮层中与专业抗原呈递细胞接触。与这种将疫苗高效递送至专业抗原呈递细胞附近的情况相关，与使用针和注射器进行肌肉内注射免疫的小鼠相比，我们实现了更优的抗体反应和统计学上相等的针对 HSV-2 病毒挑战的保护率，但抗原的递送量不到十分之一。
